Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer

• Status: Recruiting
• Trial end date: 2024-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This project aims to evaluate the efficacy and safety of oral taurine supplementation combined with PD-1 inhibitor (serplulimab) and chemotherapy in inducing systemic CD8+ T cell responses and achieving improved gastric cancer patient outcomes than with serplulimab and chemotherapy alone.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tang-Du Hospital

Criteria

Inclusion Criteria:

1. Age 18-75 years old, no gender limitation;

2. Pathologically confirmed gastric or gastroesophageal junction adenocarcinoma with cTNM stage II/III;

3. Expected survival of ≥ 3 months;

4. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;

5. Patients informed about the purpose and course of the study and provided a written consent to participate.

Exclusion Criteria:

1. Use of taurine agent within 1 month prior to the first dose of study treatment and throughout the study;

2. Patients with positive HER-2 and willing to receive herceptin treatment;

3. Patients with gastrointestinal obstruction or active bleeding in the gastrointestinal tract, as well as perforation and dysphagia;

4. Patients with severe heart, lung, liver, kidney, endocrine, hematopoietic system or psychiatric diseases were considered not suitable for the study group;

5. Patients with other medical conditions that interfere with the trial and are deemed unsuitable for inclusion in the trial by the investigator;

6. Other conditions that the investigator thinks are not suitable to participate in this clinical trial.